The trial met its primary endpoint as adjuvant atezolizumab significantly improved the DFS in patients with stage II-IIIA PD-L1 ≥1% NSCLC over best supportive care (median DFS: not reached, NR vs. 35.3 months, HR: 0.66; 95% CI: 0.5–0.88; p = 0.004) [31]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.